nach oben

Rheumatology International

Erschienen in:

28.06.2023 | Patient Opinion

Clinical characteristics of patients with hypermobile type Ehlers–Danlos syndrome (hEDS) and generalized hypermobility spectrum disorders (G-HSD): an online survey

verfasst von: Patricia Teran-Wodzinski, Ambuj Kumar

Erschienen in: Rheumatology International | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

To examine the perspective of individuals with Hypermobile Ehlers–Danlos Syndrome (hEDS) and Generalized Hypermobility Spectrum Disorder (G-HSD), needed to help identify priorities and improve the lives of people living with these conditions. We conducted an online survey between November 2021 and January 2023. Participants were recruited through the Ehlers-Danlos Society’s Research Surveys website. We obtained 483 responses and 396 were analyzed. 80% of the survey’s respondents were individuals with hEDS, 90% were females, 30% were between 21 and 30, and 76% lived in North America, with 85% of the participants living in North America indicated being White or European American. Participants reported exercising from none to less than three times per week, with no physical therapy treatment. Ninety-eight percent of participants reported pain mainly at the neck (76%), lower (76%) and upper back (66%), knees (64%), shoulders (60%), and hips (60%). Approximately 80% of participants reported fatigue, joint hypermobility, joint instability, interference with daily activities, gastrointestinal problems, orthostatic hypotension, muscle weakness, and emotional distress. About 60% of respondents indicated walking issues, balance issues, and reduced joint proprioception. Nearly 40% of participants reported pelvic floor dysfunction and cardiovascular problems. Participants with hEDS and G-HSD reported pain on an average (SD) of 6.4 (± 1.3) and 5.9 (± 1.5) days in a typical week, respectively. People with hEDS and G-HSD desperately need more effective treatment options, a better diagnostic process, and education among health care providers.

Nur mit Berechtigung zugänglich

Palmer S et al (2016) Physiotherapy management of joint hypermobility syndrome—a focus group study of patient and health professional perspectives. Physiotherapy 102(1):93–102PubMedCrossRef

Tinkle B, et al. (2017) Hypermobile Ehlers–Danlos syndrome (a.k.a. Ehlers–Danlos syndrome Type III and Ehlers–Danlos syndrome hypermobility type): clinical description and natural history. Am J Med Genet C Semin Med Genet 175(1):48–69

Malfait F et al (2017) The 2017 international classification of the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet 175(1):8–26PubMedCrossRef

Demmler JC et al (2019) Diagnosed prevalence of Ehlers–Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison. BMJ Open 9(11):e031365–e031365PubMedPubMedCentralCrossRef

Hakim AJ, Tinkle BT, Francomano CA (2021) Ehlers–Danlos syndromes, hypermobility spectrum disorders, and associated co-morbidities: reports from EDS ECHO. Am J Med Genet C Semin Med Genet 187(4):413–415PubMedCrossRef

Scheper MC et al (2016) Disability in adolescents and adults diagnosed with hypermobility-related disorders: a meta-analysis. Arch Phys Med Rehabil 97(12):2174–2187PubMedCrossRef

Engelbert RH et al (2017) The evidence-based rationale for physical therapy treatment of children, adolescents, and adults diagnosed with joint hypermobility syndrome/hypermobile Ehlers–Danlos syndrome. Am J Med Genet C Semin Med Genet 175(1):158–167PubMedCrossRef

Levy HP (1993) Hypermobile Ehlers–Danlos syndrome. In: Adam MP, et al (eds) GeneReviews(®), University of Washington, Seattle

Pacey V et al (2015) Joint hypermobility syndrome: a review for clinicians. J Paediatr Child Health 51(4):373–380PubMedCrossRef

10.

Rombaut L et al (2010) Musculoskeletal complaints, physical activity and health-related quality of life among patients with the Ehlers–Danlos syndrome hypermobility type. Disabil Rehabil 32(16):1339–1345PubMedCrossRef

11.

Voermans NC et al (2010) Pain in Ehlers–Danlos syndrome is common, severe, and associated with functional impairment. J Pain Symptom Manag 40(3):370–378CrossRef

12.

Tinkle BT (2020) Symptomatic joint hypermobility. Best Pract Res Clin Rheumatol 34(3):101508PubMedCrossRef

13.

Kumar B, Lenert P (2017) Joint hypermobility syndrome: recognizing a commonly overlooked cause of chronic pain. Am J Med 130(6):640–647PubMedCrossRef

14.

Tran ST et al (2020) Symptom complaints and impact on functioning in youth with hypermobile Ehlers–Danlos syndrome. J Child Health Care 24(3):444–457PubMedCrossRef

15.

Hakim A et al (2017) Chronic fatigue in Ehlers–Danlos syndrome–Hypermobile type. Am J Med Genet C Semin Med Genet 175(1):175–180PubMedCrossRef

16.

Palomo-Toucedo IC, et al (2020) Psychosocial influence of Ehlers–Danlos syndrome in daily life of patients: a qualitative study. Int J Environ Res Public Health 17(17)

17.

Hope L et al (2019) Subjective health complaints and illness perception amongst adults with joint hypermobility syndrome/Ehlers–Danlos syndrome-hypermobilitytype—a cross-sectional study. Disabil Rehabil 41(3):333–340PubMedCrossRef

18.

Palmer S, et al (2019) The views of people with joint hypermobility syndrome on its impact, management and the use of patient-reported outcome measures. A thematic analysis of open-ended questionnaire responses. Musculoskel Care 17(2):183–193

19.

Clark NL et al (2023) The biopsychosocial impact of hypermobility spectrum disorders in adults: a scoping review. Rheumatol Int 43(6):985–1014PubMedPubMedCentralCrossRef

20.

Aubry-Rozier B et al (2021) Are patients with hypermobile Ehlers–Danlos syndrome or hypermobility spectrum disorder so different? Rheumatol Int 41(10):1785–1794PubMedPubMedCentralCrossRef

21.

Clark NL, et al (2023) The biopsychosocial impact of hypermobility spectrum disorders in adults: a scoping review. Rheumatol Int 43(6):985–1014

22.

Yew KS, Kamps-Schmitt KA, Borge R (2021) Hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders. Am Fam Phys 103(8):481–492

23.

Robinson ME et al (2005) Multidimensional success criteria and expectations for treatment of chronic pain: the patient perspective. Pain Med 6(5):336–345PubMedCrossRef

24.

O’Brien EM et al (2010) Patient-centered perspective on treatment outcomes in chronic pain. Pain Med 11(1):6–15PubMedCrossRef

25.

Fischer D et al (1999) Capturing the patient’s view of change as a clinical outcome measure. JAMA 282(12):1157–1162PubMedCrossRef

26.

Laine C, Davidoff F (1996) Patient-centered medicine. A professional evolution. JAMA 275(2):152–156PubMedCrossRef

27.

Zeppieri G Jr et al (2012) Preliminary results of patient-defined success criteria for individuals with musculoskeletal pain in outpatient physical therapy settings. Arch Phys Med Rehabil 93(3):434–440PubMedCrossRef

28.

Zeppieri G, George SZ (2017) Patient-defined desired outcome, success criteria, and expectation in outpatient physical therapy: a longitudinal assessment. Health Qual Life Outcomes 15(1):29

29.

Wilson AT, George SZ, Bialosky JE (2019) Patient-defined outcomes for pain, fatigue, emotional distress, and interference with activities did not differ by age for individuals with musculoskeletal pain. Pain Rep 4(6):e798PubMedCrossRef

30.

Levy HP (2004) Hypermobile Ehlers–Danlos Syndrome. [Updated 2018 Jun 21]. In: Adam MP, A.H., Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2018.

31.

Eysenbach G (2004) Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res 6(3):e34PubMedPubMedCentralCrossRef

32.

Sharma A et al (2021) A consensus-based checklist for reporting of survey studies (CROSS). J Gen Intern Med 36(10):3179–3187PubMedPubMedCentralCrossRef

33.

Gaur PS et al (2020) Reporting survey based studies—a primer for authors. J Korean Med Sci 35(45):e398PubMedPubMedCentralCrossRef

34.

Castori M et al (2017) A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet 175(1):148–157PubMedCrossRef

35.

Castori M, et al (2010) Natural history and manifestations of the hypermobility type Ehlers–Danlos syndrome: a pilot study on 21 patients. Am J Med Genet A 152a(3):556–64

36.

Gensemer C et al (2021) Hypermobile Ehlers–Danlos syndromes: complex phenotypes, challenging diagnoses, and poorly understood causes. Dev Dyn 250(3):318–344PubMedCrossRef

37.

Castori M, et al (2010) Ehlers–Danlos syndrome hypermobility type and the excess of affected females: possible mechanisms and perspectives. Am J Med Genet A 152a(9): 2406–2408

38.

Russek LN, Errico DM (2016) Prevalence, injury rate and symptom frequency in generalized joint laxity and joint hypermobility syndrome in a “healthy” college population. Clin Rheumatol 35(4):1029–1039PubMedCrossRef

39.

Santore RF et al (2020) Hypermobility assessment in 1,004 adult patients presenting with hip pain: correlation with diagnoses and demographics. J Bone Joint Surg Am 102(Suppl 2):27–33PubMedCrossRef

40.

Wijnhoven HA, de Vet HC, Picavet HS (2006) Prevalence of musculoskeletal disorders is systematically higher in women than in men. Clin J Pain 22(8):717–724PubMedCrossRef

41.

Hakim A, Grahame R (2003) Joint hypermobility. Best Pract Res Clin Rheumatol 17(6):989–1004PubMedCrossRef

42.

Nicholson LL et al (2022) International perspectives on joint hypermobility: a synthesis of current science to guide clinical and research directions. J Clin Rheumatol 28(6):314–320PubMedPubMedCentralCrossRef

43.

De Baets S et al (2021) Patient perspectives on employment participation in the “hypermobile Ehlers–Danlos syndrome.” Disabil Rehabil 43(5):668–677PubMedCrossRef

44.

Murray B, et al (2013) Ehlers–Danlos syndrome, hypermobility type: a characterization of the patients' lived experience. Am J Med Genet A 161a(12):2981–2988

45.

Hamilton PR, Hulme JA, Harrison ED (2023) Experiences of higher education for students with chronic illnesses. Disabil Soc 38(1):21–46CrossRef

46.

Estrella E, Frazier PA (2023) Healthcare experiences among adults with hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorder in the United States. Disabil Rehabil. https://doi.org/10.1080/09638288.2023.2176554

47.

Anderson LK, Lane KR (2021) The diagnostic journey in adults with hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders. J Am Assoc Nurse Pract 34(4):639–648PubMedCrossRef

48.

Garreth Brittain M, et al (2023) Physical therapy interventions in generalized hypermobility spectrum disorder and hypermobile Ehlers–Danlos syndrome: a scoping review. Disabil Rehabil, pp 1–18

49.

Palmer S et al (2014) The effectiveness of therapeutic exercise for joint hypermobility syndrome: a systematic review. Physiotherapy 100(3):220–227PubMedCrossRef

50.

Alomari M et al (2020) Prevalence and predictors of gastrointestinal dysmotility in patients with hypermobile Ehlers–Danlos syndrome: a tertiary care center experience. Cureus 12(4):e7881PubMedPubMedCentral

51.

Tai FWD et al (2020) Functional gastrointestinal disorders are increased in joint hypermobility-related disorders with concomitant postural orthostatic tachycardia syndrome. Neurogastroenterol Motil 32(12):e13975PubMedCrossRef

52.

Lammers K et al (2012) Pelvic organ prolapse and collagen-associated disorders. Int Urogynecol J 23(3):313–319PubMedCrossRef

53.

Zhou W et al (2022) Anorectal manometry for the diagnosis of pelvic floor disorders in patients with hypermobility spectrum disorders and hypermobile Ehlers–Danlos syndrome. BMC Gastroenterol 22(1):538PubMedPubMedCentralCrossRef

54.

DiBaise JK, Harris LA, Goodman B (2018) Postural tachycardia syndrome (POTS) and the GI tract: a primer for the gastroenterologist. Am J Gastroenterol 113(10):1458–1467PubMedCrossRef

55.

Kohn A, Chang C (2020) The relationship between hypermobile Ehlers–Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS). Clin Rev Allergy Immunol 58(3):273–297PubMedCrossRef

56.

Orozco-Beltran D et al (2017) Telemedicine in primary care for patients with chronic conditions: the valcrònic quasi-experimental study. J Med Internet Res 19(12):e400PubMedPubMedCentralCrossRef

57.

Rolstad S, Adler J, Rydén A (2011) Response burden and questionnaire length: is shorter better? A review and meta-analysis. Value Health 14(8):1101–1108PubMedCrossRef

Titel: Clinical characteristics of patients with hypermobile type Ehlers–Danlos syndrome (hEDS) and generalized hypermobility spectrum disorders (G-HSD): an online survey
verfasst von: Patricia Teran-Wodzinski
Ambuj Kumar
Publikationsdatum: 28.06.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 10/2023
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-023-05378-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2023

Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations

Idiopathic granulomatous mastitis: clinical, histopathological, and radiological characteristics and management approaches

The relationship of neutrophil-to-lymphocyte ratio with health-related quality of life, depression, and disease activity in SLE: a cross-sectional study

The preferred technique for knee synovium biopsy and synovial fluid arthrocentesis

Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study